This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hashimoto, T. Articles by Tsuchiya, E. Search for Related Content PubMed PubMed Citation Articles by Hashimoto, T. Articles by Tsuchiya, E.

p53 Null Mutations Undetected by Immunohistochemical Staining Predict a Poor Outcome with Early-Stage Non-Small Cell Lung Carcinomas¹

Laboratory of Cancer Diagnosis and Therapy, Saitama Cancer Center Research Institute, Saitama 362-0806, Japan [T. H., Y. T., M. H., S. H., E. T.]; Department of Pathology, Saitama Cancer Center Hospital, Saitama 362-0806, Japan [Y. K., K. Ni., E. T.]; Department of Pathology, Cancer Institute, Tokyo 170-0012, Japan [Y. I.]; Department of Chest Surgery, Cancer Institute Hospital, Tokyo 170-0012, Japan [S. T., K. Na.]; Department of Thoracic and Cardiovascular Surgery, Niigata University School of Medicine, Niigata 951-8122, Japan [T. H., J. H.]

The importance of p53 mutations in the pathogenesis of human lung carcinoma is well established, but it is still controversial whether the presence of p53 mutations or overexpression of p53 protein adversely affects an individual patient’s chances of survival. The controversy may be partially due to the methodological differences in examination for p53 alterations: gene analysis or immunohistochemical staining. Furthermore, recent studies have suggested that different types of mutations of the p53 tumor suppressor gene confer different biological properties. To clarify the relationship between immunohistochemical staining and prognosis, we investigated mutations using single-strand conformation polymorphism followed by sequencing for exons 4–8 and 10 in 144 surgically treated non-small cell lung carcinoma patients with intensive clinical follow-up. Of 144 cases, 107 adenocarcinomas were examined for immunohistochemical staining with RSP53 antibody. p53 gene mutations were observed in 65 tumors (45%), including 44 missense and 21 null mutations, the latter comprising 7 nonsense mutations, 8 deletions, 2 insertions, and 4 splicing junction mutations. Presence of p53 mutations was an independent prognostic factor with a statistical trend (P = 0.14) in stage I patients but not in all cases. When examined by mutational pattern, null mutation was a significant indicator of poor outcome by multivariate analysis (P = 0.03) in stage I patients, whereas cases with missense mutations and without mutations did not differ (P = 0.76). Forty (37%) tumors demonstrated overexpression of the p53 protein but without any survival difference. Most tumors (76%) with missense mutations were immunopositive, but those with null mutations with one exception (93%) were not, and the concordance between the mutations and immunohistochemical staining was rather low at 65%. These data suggest that the type of p53 mutation is important for prediction of outcome in early-stage non-small cell lung carcinoma patients, whereas immunohistochemical staining for abnormal p53 gene products is nonpredictive. Furthermore, null mutations causing loss of function of the gene product may play more important roles than missense mutations in tumor progression.

This article has been cited by other articles:

				A. M. Mulligan, D. Pinnaduwage, S. B. Bull, F. P. O'Malley, and I. L. Andrulis Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node-Negative Cohort Clin. Cancer Res., July 1, 2008; 14(13): 4168 - 4174. [Abstract] [Full Text] [PDF]

				A Psyrri, P Kountourakis, Z Yu, C Papadimitriou, S Markakis, R. Camp, T Economopoulos, and M. Dimopoulos Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets Ann. Onc., April 1, 2007; 18(4): 709 - 715. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				R. L. Camp, M. Dolled-Filhart, and D. L. Rimm X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization Clin. Cancer Res., November 1, 2004; 10(21): 7252 - 7259. [Abstract] [Full Text] [PDF]

				F Bataille, P Rummele, W Dietmaier, D Gaag, F Klebl, A Reichle, P Wild, F Hofstadter, and A Hartmann Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer Mol. Pathol., October 1, 2003; 56(5): 286 - 292. [Abstract] [Full Text] [PDF]

				S. L. Rose, A. D. Robertson, M. J. Goodheart, B. J. Smith, B. R. DeYoung, and R. E. Buller The Impact of p53 Protein Core Domain Structural Alteration on Ovarian Cancer Survival Clin. Cancer Res., September 15, 2003; 9(11): 4139 - 4144. [Abstract] [Full Text] [PDF]

				C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]

				R.-S. Lai, J.-S. Wang, H.-K. Hsu, H.-C. Chang, C.-H. Lin, and M.-H. Lin Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 393 - 397. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al. Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743. [Abstract] [Full Text] [PDF]

				T. Koga, S. Hashimoto, K. Sugio, I. Yoshino, S. Mojtahedzadeh, Y. Matsuo, Y. Yonemitsu, K. Sugimachi, and K. Sueishi Clinicopathological and Molecular Evidence Indicating the Independence of Bronchioloalveolar Components from Other Subtypes of Human Peripheral Lung Adenocarcinoma Clin. Cancer Res., June 1, 2001; 7(6): 1730 - 1738. [Abstract] [Full Text] [PDF]

				E. Okuda, H. Osugi, K. Morimura, N. Takada, M. Takemura, S. Fukushima, M. Higashino, and H. Kinoshita Detection of p53 Gene Mutations in Human Esophageal Squamous Cell Carcinomas Using a p53 Yeast Functional Assay: Possible Difference in Esophageal Carcinogenesis Between the Young and the Elderly Group Clin. Cancer Res., March 1, 2001; 7(3): 600 - 606. [Abstract] [Full Text]

				T. Hashimoto, Y. Tokuchi, M. Hayashi, Y. Kobayashi, K. Nishida, S.-i. Hayashi, Y. Ishikawa, K. Nakagawa, J.-i. Hayashi, and E. Tsuchiya Different Subtypes of Human Lung Adenocarcinoma Caused by Different Etiological Factors : Evidence from p53 Mutational Spectra Am. J. Pathol., December 1, 2000; 157(6): 2133 - 2141. [Abstract] [Full Text] [PDF]

				T. Grundei, H. Vogelsang, K. Ott, J. Mueller, M. Scholz, K. Becker, U. Fink, J. R. Siewert, H. Höfler, and G. Keller Loss of Heterozygosity and Microsatellite Instability as Predictive Markers for Neoadjuvant Treatment in Gastric Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4782 - 4788. [Abstract] [Full Text]

				T. Hashimoto, Y. Kobayashi, Y. Ishikawa, S. Tsuchiya, S. Okumura, K. Nakagawa, Y. Tokuchi, M. Hayashi, K. Nishida, S.-i. Hayashi, et al. Prognostic Value of Genetically Diagnosed Lymph Node Micrometastasis in Non-Small Cell Lung Carcinoma Cases Cancer Res., November 1, 2000; 60(22): 6472 - 6478. [Abstract] [Full Text]

				M. G. C. T. van Oijen and P. J. Slootweg Gain-of-Function Mutations in the Tumor Suppressor Gene p53 Clin. Cancer Res., June 1, 2000; 6(6): 2138 - 2145. [Abstract] [Full Text]